{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:20:43Z","timestamp":1793830843580,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00520-020-05709-1","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T22:09:35Z","timestamp":1598566175000},"page":"6175-6181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities"],"prefix":"10.1007","volume":"28","author":[{"given":"Tim","family":"Cooksley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Girotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ginex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Blidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie R.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"5709_CR1","doi-asserted-by":"publisher","unstructured":"Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration (2018) The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr 2(3): 21. doi: https:\/\/doi.org\/10.1093\/jncics\/pky021.","DOI":"10.1093\/jncics\/pky021"},{"issue":"7","key":"5709_CR2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"C Higham","year":"2018","unstructured":"Higham C, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ, Society for Endocrinology Clinical Committee (2018) Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1\u2013G7. https:\/\/doi.org\/10.1530\/EC-18-0068","journal-title":"Endocr Connect"},{"issue":"2","key":"5709_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow M, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371\u2013381. https:\/\/doi.org\/10.1530\/ERC-13-0499","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"5709_CR4","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1530\/EJE-17-0009","volume":"179","author":"MN Joshi","year":"2018","unstructured":"Joshi MN, Whitelaw BC, Carroll PV (2018) Mechanisms in endocrinology: hypophysitis: diagnosis and treatment. Eur J Endocrinol 179(3):R151\u2013R163. https:\/\/doi.org\/10.1530\/EJE-17-0009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"5709_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.52964\/AMJA.0647","volume":"16","author":"P Webb","year":"2017","unstructured":"Webb P, Rice TW, Cooksley T (2017) Problem-based review: immune-mediated complications of \u201ccheckpoint inhibitors\u201d for the acute physician. Acute Med 16(1):21\u201324","journal-title":"Acute Med"},{"issue":"1","key":"5709_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"issue":"8","key":"5709_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilumumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"2","key":"5709_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"issue":"4","key":"5709_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB (2015) Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21(4):749\u2013755. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2353","journal-title":"Clin Cancer Res"},{"issue":"18","key":"5709_CR10","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, Sullivan RJ (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706\u20133714. https:\/\/doi.org\/10.1002\/cncr.31629","journal-title":"Cancer"},{"issue":"12","key":"5709_CR11","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, Taverna G, Cosottini M, Lupi I (2016) Hypophysitis secondary to cytotoxic T-lymphocyte associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186(12):3225\u20133235. https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"issue":"230","key":"5709_CR12","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6(230):230ra45. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"issue":"4","key":"5709_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, Fran\u00e7ois H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574. https:\/\/doi.org\/10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"issue":"2","key":"5709_CR14","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F (2019) French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26(2):G1\u2013G18. https:\/\/doi.org\/10.1530\/ERC-18-0320","journal-title":"Endocr Relat Cancer"},{"issue":"24","key":"5709_CR15","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1002\/cncr.31789","volume":"124","author":"T Cooksley","year":"2018","unstructured":"Cooksley T, Higham C, Lorigan P, Trainer P (2018) Emergency management of immune-related hypophysitis: collaboration between specialists is essential to achieve optimal outcomes. Cancer 124(24):4731. https:\/\/doi.org\/10.1002\/cncr.31789","journal-title":"Cancer"},{"issue":"11","key":"5709_CR16","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 99(11):4078\u20134085. https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"5709_CR17","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 102(8):2770\u20132780. https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"5709_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"issue":"11","key":"5709_CR19","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101(11):4431\u20134439. https:\/\/doi.org\/10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"5709_CR20","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1210\/jc.2014-4560","volume":"100","author":"S Orlov","year":"2015","unstructured":"Orlov S, Salari F, Kashat L, Walfish PG (2015) Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100(5):1738\u20131741. https:\/\/doi.org\/10.1210\/jc.2014-4560","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"5709_CR21","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM (2014) Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid 24(12):1670\u20131751. https:\/\/doi.org\/10.1089\/thy.2014.0028","journal-title":"Thyroid"},{"issue":"4","key":"5709_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000356507","volume":"2","author":"SH Pearce","year":"2013","unstructured":"Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, Wemeau JL (2013) 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J 2(4):215\u2013228. https:\/\/doi.org\/10.1159\/000356507","journal-title":"Eur Thyroid J"},{"issue":"6","key":"5709_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","volume":"7","author":"AL Perdigoto","year":"2019","unstructured":"Perdigoto AL, Quandt Z, Anderson M, Herold KC (2019) Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. Lancet Diabetes Endocrinol 7(6):421\u2013423. https:\/\/doi.org\/10.1016\/S2213-8587(19)30072-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5709_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67980","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC (2018) Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67980:1471\u20131480. https:\/\/doi.org\/10.2337\/dbi18-0002","journal-title":"Diabetes"},{"issue":"11","key":"5709_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","volume":"66","author":"ML Gauci","year":"2017","unstructured":"Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebb\u00e9 C, Gautier JF (2017) Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother 66(11):1399\u20131410. https:\/\/doi.org\/10.1007\/s00262-017-2033-8","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"5709_CR26","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.2337\/dc18-1465","volume":"41","author":"JJ Wright","year":"2018","unstructured":"Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC (2018) Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care 41(12):e150\u2013e151. https:\/\/doi.org\/10.2337\/dc18-1465","journal-title":"Diabetes Care"},{"issue":"5","key":"5709_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","volume":"76","author":"N Yamazaki","year":"2015","unstructured":"Yamazaki N, Kiyohara Y, Uhara H, Fukushima S, Uchi H, Shibagaki N, Tsutsumida A, Yoshikawa S, Okuyama R, Ito Y, Tokudome T (2015) Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol 76(5):997\u20131004. https:\/\/doi.org\/10.1007\/s00280-015-2873-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"5709_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","volume":"130","author":"T Cooksley","year":"2020","unstructured":"Cooksley T, Gupta A, Al-Sayed T, Lorigan P (2020) Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer 130:193\u2013197","journal-title":"Eur J Cancer"},{"key":"5709_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CCO.0000000000000635","volume":"32","author":"T Cooksley","year":"2020","unstructured":"Cooksley T, Stutman R, Klotz A (2020) Emergency management of immune-related toxicity. Curr Opin Oncol 32:274\u2013281. https:\/\/doi.org\/10.1097\/CCO.0000000000000635","journal-title":"Curr Opin Oncol"},{"issue":"31","key":"5709_CR30","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","volume":"35","author":"T Gilligan","year":"2017","unstructured":"Gilligan T, Coyle N, Frankel RM, Berry DL, Bohlke K, Epstein RM, Finlay E, Jackson VA, Lathan CS, Loprinzi CL, Nguyen LH, Seigel C, Baile WF (2017) Patient-clinician communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 35(31):3618\u20133632. https:\/\/doi.org\/10.1200\/JCO.2017.75.2311","journal-title":"J Clin Oncol"},{"issue":"2 suppl","key":"5709_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1188\/17.CJON.S2.13-21","volume":"21","author":"V Bayer","year":"2017","unstructured":"Bayer V, Amaya B, Baniewicz D, Callahan C, Marsh L, McCoy AS (2017) Cancer immunotherapy: an evidence-based overview and implications for practice. Clin J Oncol Nurs 21(2 suppl):13\u201321. https:\/\/doi.org\/10.1188\/17.CJON.S2.13-21","journal-title":"Clin J Oncol Nurs"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05709-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:08:03Z","timestamp":1630022883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05709-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5709"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05709-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB, RA, JC, TC, PG, DG, RAG, and VRS have no conflict of interest to declare. MD reports grants from Novartis, other (SAB) from Neoleukin Therapeutics, personal fees from Partner Therapeutics, personal fees from Tillotts Pharma, and grants from Genentech, outside the submitted work. MG reports consultant work with Bristol Myers Squibb (BMS) and AstraZeneca, outside the submitted work. IG reports other (Stock Ownership) from Pfizer Inc. and personal fees from CytomX Inc, outside the submitted work. DBJ reports other (advisory board) from Array Biopharma, grants and other (advisory board) from BMS, other (advisory board) from Jansen, grants from Incyte, other (advisory board) from Merck, and other (advisory board) from Novartis, outside the submitted work. BLR reports personal fees and other (advisory board) from Merck and Co; grants, personal fees, and other (advisory board) from BMS; grants, personal fees, and other (advisory board) from Roche South Africa; and personal fees and other (advisory board) from AstraZeneca, during the conduct of the study. MSA reports personal fees from Gilead, grants from Pfizer, and personal fees from Abbvie, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}